Moderna (MRNA) Starts Ebola Vaccine Trial As Fair Value Questions Persist
Health Canada has cleared Moderna (MRNA) to begin a Phase I clinical trial of its mRNA Ebola vaccine targeting the Bundibugyo virus, giving investors another data point on the company’s expanding infectious disease pipeline.
See our latest analysis for Moderna.
Moderna’s US$63.32 share price has been volatile, with a 7.01% 7 day share price gain and a 29.12% 90 day share price return. The 125.98% 1 year total shareholder return contrasts with a weaker 3 and 5 year record. Recent regulatory progress on mFlusiva and the new Ebola candidate trial adds to a period where investors appear to be reassessing both growth potential and the risks around its vaccine portfolio.
If Moderna’s pipeline has your attention, this is also a useful moment to scan other healthcare opportunities and see which vaccine and treatment platforms are gaining traction through 44 healthcare AI stocks
After Moderna’s sharp 1 year rebound and fresh product wins, the key issue now is whether investors are still early in a recovery story or already paying up for most of the good news. The valuation section addresses that next.
Most Popular Narrative: 43.1% Overvalued
Moderna’s most followed narrative pegs fair value at $44.25 per share, which sits well below the recent $63.32 close, so the story leans heavily on future pipeline execution and margin repair.
The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID-19, including recent positive late-stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases, are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top-line growth.
Want to see what sits behind that flu and oncology optimism for Moderna. The narrative leans on faster revenue growth, higher margins and a richer future earnings multiple. Curious how those moving parts combine into a single fair value number.
Result: Fair Value of $44.25 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to factor in risks such as slower than expected uptake of new vaccines and tighter drug pricing policies that could challenge the Moderna story.
Find out about the key risks to this Moderna narrative.
Next Steps
If this mix of optimism and caution around Moderna leaves you undecided, move quickly and review the data yourself. You can start by checking the 1 key reward
Looking for more investment ideas beyond Moderna?
Do not stop with just one stock. Use this moment to line up your next moves with a few focused sets of companies that match your goals.
- Target potential bargains by scanning for quality companies that appear mispriced through the 50 high quality undervalued stocks
- Prioritize resilience and sleep better at night by reviewing the 83 resilient stocks with low risk scores
- Hunt for lesser known opportunities with strong fundamentals using the screener containing 18 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com